{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:10:55Z","timestamp":1781021455131,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.eururo.2005.01.012","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T12:33:59Z","timestamp":1107261239000},"page":"575-581","source":"Crossref","is-referenced-by-count":32,"title":["Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate"],"prefix":"10.1016","volume":"47","author":[{"given":"Carlo","family":"Magno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Anastasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziata","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Maisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Franchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gal\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Frisina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin","family":"Melloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2005.01.012_bib1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer","volume":"311","author":"Garnick","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2005.01.012_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2005.01.012_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2005.01.012_bib6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","article-title":"Fracture risk following bilateral orchiectomy","volume":"169","author":"Melton","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib8","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410X.2003.04471.x","article-title":"Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation","volume":"92","author":"Hussain","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2005.01.012_bib10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-naive men with prostate carcinoma","volume":"9","author":"Smith","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2005.01.012_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jc.87.2.599","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2005.01.012_bib12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","article-title":"Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2005.01.012_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur. Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00345-003-0322-7","article-title":"The non steroidal antiandrogen, bicalutamide (casodex), may preserve bone mineral density as compared with castration: results of a preliminary study","volume":"21","author":"Tyrrell","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2005.01.012_bib16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2005.01.012_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eursup.2004.08.012","article-title":"Cancer treatment induce bone loss in prostate cancer: pathophysiology preclinical findings and treatment with zoledronic acid","author":"Guise","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2005.01.012_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2005.01.012_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-9343(87)90699-1","article-title":"Beneficial effects of aminohexane bisphosphonate in patients with Paget's disease of bone resistant to sodium etidronate","volume":"83","author":"Delmas","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.eururo.2005.01.012_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S8756-3282(98)00133-1","article-title":"Paget's disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate","volume":"23","author":"Filipponi","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.eururo.2005.01.012_bib21","first-page":"55","article-title":"Short-term intravenous therapy with Neridronate in Paget's disease","volume":"20","author":"Adami","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.eururo.2005.01.012_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.1994.176","article-title":"Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)","volume":"69","author":"O\u2019Rourke","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2005.01.012_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.eururo.2005.01.012_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2005.01.012_bib25","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.87.8.3656","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2005.01.012_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"5","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2005.01.012_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2003.10.003","article-title":"Role of Bisphosphonates in Prostate Cancer","volume":"45","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.eururo.2005.01.012_bib28","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/01.ju.0000141515.67372.e5","article-title":"The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate","volume":"172","author":"Bae","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2005.01.012_bib29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.263.5.665","article-title":"Appendicular bone density and age predict hip fracture in women","volume":"263","author":"Cummings","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2005.01.012_bib30","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1210\/jc.84.6.1966","article-title":"Effect of testosterone treatment on bone mineral density in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2005.01.012_bib31","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1210\/jc.81.12.4358","article-title":"Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism","volume":"81","author":"Katznelson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2005.01.012_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1210\/jcem-69-4-776","article-title":"Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism","volume":"69","author":"Finkelstein","year":"1989","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T14:43:28Z","timestamp":1586097808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283805000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0302283805000291"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2005.01.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}